Do analysts rate SWAG or MXCT?

MaxCyte has a consensus price target of $5.50, indicating a potential upside of 347.15%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than Stran & Company, Inc.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stran & Company, Inc. 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 MaxCyte 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better valuation and earnings, SWAG or MXCT?

Stran & Company, Inc. has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stran & Company, Inc. $116.19M 0.34 -$750K $0.01 212.00 MaxCyte $33.03M 3.99 -$44.63M -$0.37 N/A

Do analysts prefer SKLZ or SWAG?

Skillz currently has a consensus target price of $15.00, suggesting a potential upside of 68.54%. Given Skillz's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skillz is more favorable than Stran & Company, Inc.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skillz 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Stran & Company, Inc. 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, SKLZ or SWAG?

Stran & Company, Inc. has higher revenue and earnings than Skillz. Skillz is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skillz $104.50M 1.33 -$70.41M -$3.48 N/A Stran & Company, Inc. $116.19M 0.34 -$750K $0.01 212.00

Is SKLZ or SWAG more profitable?

Stran & Company, Inc. has a net margin of 0.33% compared to Skillz's net margin of -48.49%. Stran & Company, Inc.'s return on equity of 1.26% beat Skillz's return on equity. Company Net Margins Return on Equity Return on Assets Skillz -48.49% -52.81% -20.87% Stran & Company, Inc. 0.33% 1.26% 0.73%

Do analysts rate SWAG or FIRY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stran & Company, Inc. 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Skillz 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SWAG or FIRY?

Stran & Company, Inc. has higher revenue and earnings than Skillz. Skillz is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stran & Company, Inc. $116.19M 0.34 -$750K $0.01 212.00 Skillz $104.50M 1.31 -$70.41M -$3.48 N/A

Is SWAG or FIRY more profitable?

Stran & Company, Inc. has a net margin of 0.33% compared to Skillz's net margin of -48.49%. Stran & Company, Inc.'s return on equity of 1.26% beat Skillz's return on equity. Company Net Margins Return on Equity Return on Assets Stran & Company, Inc. 0.33% 1.26% 0.73% Skillz -48.49% -52.81% -20.87%

Do analysts prefer OPRX or SWAG?

OptimizeRx currently has a consensus target price of $13.43, indicating a potential upside of 103.65%. Given OptimizeRx's stronger consensus rating and higher probable upside, research analysts clearly believe OptimizeRx is more favorable than Stran & Company, Inc.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OptimizeRx 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Stran & Company, Inc. 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SWAG or JLHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stran & Company, Inc. 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Julong 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SWAG or JLHL?

Julong has lower revenue, but higher earnings than Stran & Company, Inc.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stran & Company, Inc. $116.19M 0.34 -$750K $0.01 212.00 Julong $35.40M 2.53 $3.67M N/A N/A

Stran & Company, Inc. (SWAG) Competitors

$2.12 +0.02 (+0.95%)

As of 11:00 AM Eastern

Compare

SWAG vs. MXCT, SKLZ, FIRY, OPRX, and JLHL

Should you buy Stran & Company, Inc. stock or one of its competitors? MarketBeat compares Stran & Company, Inc. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stran & Company, Inc. include MaxCyte (MXCT), Skillz (SKLZ), Skillz (FIRY), OptimizeRx (OPRX), and Julong (JLHL). These companies are all part of the "business services" industry.

How does Stran & Company, Inc. compare to MaxCyte?

Stran & Company, Inc. (NASDAQ:SWAG) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, MaxCyte had 2 more articles in the media than Stran & Company, Inc.. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for Stran & Company, Inc.. MaxCyte's average media sentiment score of 0.96 beat Stran & Company, Inc.'s score of 0.00 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Stran & Company, Inc.	Neutral
MaxCyte	Positive

56.4% of Stran & Company, Inc. shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 50.6% of Stran & Company, Inc. shares are owned by company insiders. Comparatively, 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Stran & Company, Inc. has a net margin of 0.33% compared to MaxCyte's net margin of -121.16%. Stran & Company, Inc.'s return on equity of 1.26% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stran & Company, Inc.	0.33%	1.26%	0.73%
MaxCyte	-121.16%	-20.03%	-17.14%

Stran & Company, Inc. has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stran & Company, Inc.	$116.19M	0.34	-$750K	$0.01	212.00
MaxCyte	$33.03M	3.99	-$44.63M	-$0.37	N/A

MaxCyte has a consensus price target of $5.50, indicating a potential upside of 347.15%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts clearly believe MaxCyte is more favorable than Stran & Company, Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stran & Company, Inc.	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Stran & Company, Inc. has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Summary

Stran & Company, Inc. beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does Stran & Company, Inc. compare to Skillz?

Skillz (NYSE:SKLZ) and Stran & Company, Inc. (NASDAQ:SWAG) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Stran & Company, Inc. has a net margin of 0.33% compared to Skillz's net margin of -48.49%. Stran & Company, Inc.'s return on equity of 1.26% beat Skillz's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skillz	-48.49%	-52.81%	-20.87%
Stran & Company, Inc.	0.33%	1.26%	0.73%

Stran & Company, Inc. has higher revenue and earnings than Skillz. Skillz is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skillz	$104.50M	1.33	-$70.41M	-$3.48	N/A
Stran & Company, Inc.	$116.19M	0.34	-$750K	$0.01	212.00

Skillz has a beta of 4.58, indicating that its share price is 358% more volatile than the broader market. Comparatively, Stran & Company, Inc. has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Skillz currently has a consensus target price of $15.00, suggesting a potential upside of 68.54%. Given Skillz's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skillz is more favorable than Stran & Company, Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skillz	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Stran & Company, Inc.	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.4% of Skillz shares are held by institutional investors. Comparatively, 56.4% of Stran & Company, Inc. shares are held by institutional investors. 59.4% of Skillz shares are held by company insiders. Comparatively, 50.6% of Stran & Company, Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skillz's average media sentiment score of 0.00 equaled Stran & Company, Inc.'saverage media sentiment score.

Company	Overall Sentiment
Skillz	Neutral
Stran & Company, Inc.	Neutral

Summary

Stran & Company, Inc. beats Skillz on 8 of the 14 factors compared between the two stocks.

How does Stran & Company, Inc. compare to Skillz?

Stran & Company, Inc. (NASDAQ:SWAG) and Skillz (NYSE:FIRY) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Stran & Company, Inc.'s average media sentiment score of 0.00 equaled Skillz'saverage media sentiment score.

Company	Overall Sentiment
Stran & Company, Inc.	Neutral
Skillz	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stran & Company, Inc.	$116.19M	0.34	-$750K	$0.01	212.00
Skillz	$104.50M	1.31	-$70.41M	-$3.48	N/A

Stran & Company, Inc. has a net margin of 0.33% compared to Skillz's net margin of -48.49%. Stran & Company, Inc.'s return on equity of 1.26% beat Skillz's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stran & Company, Inc.	0.33%	1.26%	0.73%
Skillz	-48.49%	-52.81%	-20.87%

Stran & Company, Inc. has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Skillz has a beta of 4.52, suggesting that its share price is 352% more volatile than the broader market.

56.4% of Stran & Company, Inc. shares are owned by institutional investors. Comparatively, 19.4% of Skillz shares are owned by institutional investors. 50.6% of Stran & Company, Inc. shares are owned by company insiders. Comparatively, 59.4% of Skillz shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stran & Company, Inc.	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Skillz	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Stran & Company, Inc. beats Skillz on 9 of the 12 factors compared between the two stocks.

How does Stran & Company, Inc. compare to OptimizeRx?

OptimizeRx (NASDAQ:OPRX) and Stran & Company, Inc. (NASDAQ:SWAG) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

OptimizeRx has higher earnings, but lower revenue than Stran & Company, Inc.. OptimizeRx is trading at a lower price-to-earnings ratio than Stran & Company, Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.13	$5.13M	$0.35	18.84
Stran & Company, Inc.	$116.19M	0.34	-$750K	$0.01	212.00

OptimizeRx has a net margin of 6.37% compared to Stran & Company, Inc.'s net margin of 0.33%. OptimizeRx's return on equity of 10.86% beat Stran & Company, Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
Stran & Company, Inc.	0.33%	1.26%	0.73%

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 56.4% of Stran & Company, Inc. shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 50.6% of Stran & Company, Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OptimizeRx has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Stran & Company, Inc. has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, OptimizeRx had 3 more articles in the media than Stran & Company, Inc.. MarketBeat recorded 3 mentions for OptimizeRx and 0 mentions for Stran & Company, Inc.. OptimizeRx's average media sentiment score of 0.33 beat Stran & Company, Inc.'s score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Overall Sentiment
OptimizeRx	Neutral
Stran & Company, Inc.	Neutral

OptimizeRx currently has a consensus target price of $13.43, indicating a potential upside of 103.65%. Given OptimizeRx's stronger consensus rating and higher probable upside, research analysts clearly believe OptimizeRx is more favorable than Stran & Company, Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Stran & Company, Inc.	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

OptimizeRx beats Stran & Company, Inc. on 12 of the 16 factors compared between the two stocks.

How does Stran & Company, Inc. compare to Julong?

Stran & Company, Inc. (NASDAQ:SWAG) and Julong (NASDAQ:JLHL) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

56.4% of Stran & Company, Inc. shares are held by institutional investors. 50.6% of Stran & Company, Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stran & Company, Inc.	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Julong	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Stran & Company, Inc.'s average media sentiment score of 0.00 equaled Julong'saverage media sentiment score.

Company	Overall Sentiment
Stran & Company, Inc.	Neutral
Julong	Neutral

Julong has lower revenue, but higher earnings than Stran & Company, Inc..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stran & Company, Inc.	$116.19M	0.34	-$750K	$0.01	212.00
Julong	$35.40M	2.53	$3.67M	N/A	N/A

Stran & Company, Inc. has a net margin of 0.33% compared to Julong's net margin of 0.00%. Stran & Company, Inc.'s return on equity of 1.26% beat Julong's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stran & Company, Inc.	0.33%	1.26%	0.73%
Julong	N/A	N/A	N/A

Summary

Stran & Company, Inc. beats Julong on 7 of the 9 factors compared between the two stocks.

Get Stran & Company, Inc. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SWAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SWAG vs. The Competition

Export

Metric	Stran & Company, Inc.	ADVERTISING/MKTG SVCS Industry	Business Sector	NASDAQ Exchange
Market Cap	$39.52M	$2.14B	$6.85B	$12.40B
Dividend Yield	N/A	3.80%	3.04%	9.39%
P/E Ratio	212.21	30.23	28.70	24.12
Price / Sales	0.34	118.87	344.76	92.58
Price / Cash	106.68	13.11	22.57	47.25
Price / Book	1.27	16.15	5.69	6.23
Net Income	-$750K	$17.67M	$203.60M	$331.53M
7 Day Performance	6.00%	-7.29%	-1.46%	-1.30%
1 Month Performance	-2.30%	-13.46%	-2.87%	-1.40%
1 Year Performance	40.77%	159.39%	10.43%	18.15%

Stran & Company, Inc. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SWAG Stran & Company, Inc.	0.992 of 5 stars	$2.12 +1.0%	N/A	+40.6%	$39.52M	$116.19M	212.21	70
MXCT MaxCyte	3.4373 of 5 stars	$1.35 -4.9%	$5.50 +307.4%	-42.1%	$152.11M	$33.03M	N/A	80	News Coverage
SKLZ Skillz	1.7185 of 5 stars	$8.90 +0.7%	$15.00 +68.5%	+27.7%	$138.93M	$104.50M	N/A	650	Gap Down
FIRY Skillz	0.2957 of 5 stars	$8.14 -4.7%	N/A	N/A	$133.29M	$104.50M	N/A	650
OPRX OptimizeRx	4.8016 of 5 stars	$6.65 flat	$13.43 +101.9%	-49.8%	$124.79M	$109.43M	19.00	100	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SWAG) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stran & Company, Inc. (SWAG) Competitors

SWAG vs. MXCT, SKLZ, FIRY, OPRX, and JLHL

How does Stran & Company, Inc. compare to MaxCyte?

Summary

How does Stran & Company, Inc. compare to Skillz?

Summary

How does Stran & Company, Inc. compare to Skillz?

Summary

How does Stran & Company, Inc. compare to OptimizeRx?

Summary

How does Stran & Company, Inc. compare to Julong?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SWAG vs. The Competition

Stran & Company, Inc. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stran & Company, Inc. (SWAG) Competitors

SWAG vs. MXCT, SKLZ, FIRY, OPRX, and JLHL

How does Stran & Company, Inc. compare to MaxCyte?

Does the media refer more to SWAG or MXCT?

Do institutionals and insiders have more ownership in SWAG or MXCT?

Is SWAG or MXCT more profitable?

Which has better valuation and earnings, SWAG or MXCT?

Do analysts rate SWAG or MXCT?

Which has more risk & volatility, SWAG or MXCT?

Summary

How does Stran & Company, Inc. compare to Skillz?

Is SKLZ or SWAG more profitable?

Which has better valuation & earnings, SKLZ or SWAG?

Which has more risk and volatility, SKLZ or SWAG?

Do analysts prefer SKLZ or SWAG?

Do institutionals and insiders hold more shares of SKLZ or SWAG?

Does the media prefer SKLZ or SWAG?

Summary

How does Stran & Company, Inc. compare to Skillz?

Does the media refer more to SWAG or FIRY?

Which has higher earnings and valuation, SWAG or FIRY?

Is SWAG or FIRY more profitable?

Which has more volatility & risk, SWAG or FIRY?

Do insiders and institutionals hold more shares of SWAG or FIRY?

Do analysts rate SWAG or FIRY?

Summary

How does Stran & Company, Inc. compare to OptimizeRx?

Which has better earnings & valuation, OPRX or SWAG?

Is OPRX or SWAG more profitable?

Do insiders & institutionals have more ownership in OPRX or SWAG?

Which has more volatility & risk, OPRX or SWAG?

Does the media prefer OPRX or SWAG?

Do analysts prefer OPRX or SWAG?

Summary

How does Stran & Company, Inc. compare to Julong?

Do institutionals & insiders hold more shares of SWAG or JLHL?

Do analysts recommend SWAG or JLHL?

Does the media refer more to SWAG or JLHL?

Which has stronger valuation & earnings, SWAG or JLHL?

Is SWAG or JLHL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SWAG vs. The Competition

Stran & Company, Inc. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools